ArticleFrontiers in medicine2025
Comparative efficacy and safety of nitinol vs. novel fully biodegradable occluders for transcatheter patent foramen ovale closure in migraine treatment: a retrospective cohort study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Patent Foramen Ovale: Epidemiology, Risk Factors, Pathophysiology, Clinical Features, Diagnosis, and Management.MedComm · 2026Review
- Fully biodegradable versus nitinol occluder devices for transcatheter patent foramen ovale closure: a systematic review.Global cardiology science & practice · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transcatheter closure of patent foramen ovale (PFO) has shown potential therapeutic benefits for clinical symptoms in selected patients with migraine. Nevertheless, the comparative effectiveness and safety of traditional nitinol vs. fully biodegradable occluders remain to be fully elucidated and warrant further investigation. Materials and methods: This retrospective cohort study included 158 migraine patients with a confirmed patent foramen ovale (PFO) and a grade II-III right-to-left shunt (RLS) as determined by contrast-enhanced transthoracic echocardiography (cTTE), who underwent transcatheter PFO closure at Shanghai East Hospital, Tongji University, between October 2023 and January 2024. Based on the occluder type, patients were categorized into a nitinol group ( Results: Both the nitinol group and biodegradable groups showed significant reductions in MIDAS scores post-procedure with no significant difference in migraine relief between groups ( Conclusion: Both biodegradable and nitinol PFO occluders were equally effective in alleviating migraine symptoms, with excellent procedural success and safety profiles. The biodegradable occluder demonstrated effective closure and gradual degradation, offering a promising alternative to nitinol occluders, especially for patients concerned about long-term foreign body implantation. These findings support the clinical utility of both occluder types in PFO-related migraine treatment, with individualized device selection based on patient preferences and clinical factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.